Every heartbeat depends on four heart valves opening and closing perfectly to ensure blood flows in the right direction. When one of these valves narrows (stenosis) or becomes leaky (regurgitation), the heart must work harder, leading to breathlessness, fatigue, chest pain, dizziness, heart failure, or even sudden death if left untreated.
The good news is that the treatment of valve disease has evolved dramatically over the past decade. Today, many patients no longer require conventional open-heart surgery. Advances in structural heart interventions now allow selected patients to undergo Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral Valve Replacement (TMVR), and Transcatheter Edge-to-Edge Repair (TEER) through small catheters, often with quicker recovery and excellent outcomes.
The heart has four valves:
These valves ensure one-way blood flow.
Valve disease develops when a valve becomes:
Stenotic – fails to open completely.
Regurgitant – fails to close properly.
Both conditions increase the workload on the heart and can eventually lead to heart failure.
Patients may experience:
Many patients dismiss these symptoms as "old age," delaying treatment until heart function has already deteriorated.
Treatment depends on:
Today, treatment is individualised by a multidisciplinary Heart Team, including interventional cardiologists, cardiac surgeons, imaging specialists, anesthesiologists, and heart failure experts.
Whenever feasible, repairing the native valve is preferred, especially in degenerative mitral valve disease, as it preserves the patient's own valve and may reduce the need for lifelong anticoagulation.
Open-heart valve replacement remains an excellent option for many younger and low-risk patients with severe valve disease.
Mechanical valves offer excellent durability but require lifelong blood thinners, while biological valves avoid long-term anticoagulation but have a limited lifespan.
One of the biggest advances in cardiology is TAVR, where a new aortic valve is implanted through a catheter, usually inserted via the femoral artery in the groin—without opening the chest.
TAVR is especially beneficial for:
Advantages
For appropriately selected patients, TAVR has outcomes comparable to surgery while offering a less invasive treatment option.
Patients with severe mitral regurgitation who are unsuitable for surgery may benefit from TEER, a minimally invasive procedure performed through a catheter inserted via the femoral vein.
This technique clips the leaking mitral valve leaflets together, reducing regurgitation and improving symptoms without the need for open-heart surgery.
TEER has transformed the management of selected patients with both degenerative and functional mitral regurgitation.
TMVR is an emerging treatment option for selected patients with severe mitral valve disease who are not suitable for conventional surgery.
It may be considered in:
Although currently offered in specialized centers for carefully selected patients, TMVR represents the future of structural heart interventions.
Patients who previously underwent valve replacement do not always require repeat open-heart surgery when the bioprosthetic valve degenerates.
Using catheter-based technology, a new valve can often be implanted inside the old valve through Valve-in-Valve TAVR or Valve-in-Valve TMVR, avoiding another major operation.
Compared with conventional surgery, catheter-based valve therapies offer several potential advantages:
Recovery depends on the procedure performed. Most patients undergoing TAVR, TMVR, TEER begin walking within 24 hours and are discharged in 1–3 days if there are no complications. Recovery after surgical valve replacement generally requires a longer hospital stay and several weeks of rehabilitation.
Valve disease often progresses silently.
Regular evaluation with:
helps identify the optimal time for intervention—before irreversible heart damage occurs.
Successful outcomes depend on more than the procedure itself. Comprehensive structural heart programs provide:
This ensures that each patient receives the most appropriate treatment rather than a one-size-fits-all approach.
At Star Hospitals, we offer comprehensive evaluation and advanced treatment for heart valve disease, including TAVR, TMVR, TEER, valve-in-valve procedures, and surgical valve interventions. Using state-of-the-art imaging, a multidisciplinary Heart Team approach, and internationally accepted treatment protocols, we tailor therapy to each patient's clinical needs.
Whether you require conventional surgery or the latest minimally invasive structural heart intervention, our goal is to restore heart function, improve quality of life, and help you return to normal activities as quickly and safely as possible.
DR. M. HANUMANTHA REDDY | JUL 20, 2026
Minimally Invasive Cardiac Procedures: The Latest Advances in Cardiac Care
DR. ANJANI DWARAMPUDI | JUL 20, 2026
Common Mistakes Heart Patients Make in Winter and How to Avoid Them
DR. SURESH YERRA | JUL 20, 2026
Heart Transplant in Hyderabad: A New Lease of Life with the Best Cardiac Care
DR. SURESH YERRA | JUL 20, 2026
MitraClip Procedure: A Minimally Invasive Treatment for Leaky Heart Valves
DR. SREEKANTH YERRAM | JUL 20, 2026
TAVI: A Safer, Less Invasive Option for Aortic Valve Replacement
Terms & Conditions | Privacy Policy | Cancellation and Refund Policy | © 2008-2026 Star Hospitals, All Rights Reserved